On October 29, Jiyao Holdings, which had been suspended for more than four months, resumed trading on the same day, ushering in two consecutive trading days after resuming trading. In the first week of reopening, the shares of Jiyao Holdings fell three times, rose one level, and closed on November 2. The shares of Jiyao Holdings were 6.25 yuan per share. Kyrgyzstan controlled resumption of the first week, the total market value evaporated over 1 billion yuan.
On October 26, Jiyao Holdings announced that Sun Jun, chairman of Jiyao Holdings, issued an initiative calling on all employees to increase their ownership of listed companiesstocks and promised full compensation for losses and no upper limit for compensation. At the same time, reporters noticed that the monthly salary of employees was only 3,000 yuan, and the chairman himself has lost millions of dollars this year.
This year, 1 billion yuan has been bought and sold.
Since 2018, Kyrgyzstan Holdings has announced 7 investments or acquisitions, with a total value of more than 1 billion yuan. Among them, there are two cases of nominal 0 yuan transferee equity, in fact, Jiyao Holdings needs to invest 82.6 million yuan; there is also a major asset restructuring, the target within three months depreciation of more than 100 million yuan.
On April 19 this year, Jiyao Holdings announced that it intends to transfer 70% of Bozhou Pharmaceutical Holdings held by Minsheng Pharmaceutical Industry at a price of 0 yuan. On the same day, Jiyao Holdings also announced that it intends to transfer 22%, 22% and 26% of Yuanda Kanghua Holdings held by Zhao Ke, Liu Chengchao and Bai Guizhi respectively at a price of 0 yuan.
Why are these shares trading at 0 yuan? According to the announcement, the registered capital of the shares to be transfered is not paid.
But in fact, after the completion of these two equity transactions, Jiyao Holdings holds 70% of Bozhou Pharmaceutical, with a capital contribution of 70 million yuan; Jiyao Holdings holds 70% of Yuanda Kanghua, with a capital contribution of 12.6 million yuan. That is to say, the two nominal 0 yuan transferable shares, Jiyao Holdings actually need to invest 82.6 million yuan, the way of investment is cash.
On June 12, Jilin Pharmaceutical Holdings announced a major suspension announcement. It intends to purchase Puhua Pharmaceutical Equity. The transaction amount ranges from 750 million yuan to 850 million yuan.
On September 13, in the major asset purchase plan, Jiyao Holdings disclosed that, according to the income method, the estimated value of Puhua Pharmaceutical 100% equity was 620 million yuan, which was 391 million yuan higher than the book value of its net assets, and the increment rate was 170.47%. Ji medicine control purchase intends to buy 99.68% stake in Pu Hua Pharmaceutical Company, and the transaction price is tentatively set at 618 million yuan, cash transaction.
Jiyao Holdings said that after the completion of this transaction, listed companies and subsidiary Jinbao Pharmaceutical will hold 100% of Puhua Pharmaceutical. Through this transaction, the listed companies will improve their competitive advantages in the fields of Chinese patent medicine, chemical medicine and other fields, and expand their product categories to ophthalmology and other fields, so as to further optimize the business product portfolio of listed companies.
It should be pointed out that in the three months from June 12 to September 13, the trading price of PricewaterhousePharmaceuticals fell sharply, resulting in a price gap of more than 100 million yuan.
In response, Jiyao Holdings told Xinjing News on November 2 that during the suspension period, the company and the counterparty have conducted many rounds of negotiations on core business terms such as transaction price and mode, and intermediaries have conducted due diligence, auditing and evaluation of the target. In the course of business negotiation, due to the great changes in the stock secondary market, the company and Puhua Pharmaceutical shareholders ultimately negotiated to complete the acquisition in cash, and preliminarily negotiated the transaction price based on the results of the assessors estimated value and referring to the valuation level range of the cash acquisition case in the secondary market.
Suspension of over 4 months, a week after the resumption of market value evaporated over 1 billion yuan
In addition to the above acquisitions, Jiyao Holdings has made four investments or acquisitions this year, totaling 357 million yuan.
On January 30, Jilin Pharmaceutical Holdings announced that it intends to invest in Haitong Pharmaceutical Co., Ltd. together with China Pharmaceutical Holdings. Jilin Pharmaceutical Holdings invested 67.0625 million yuan to subscribe for the new registered capital of Haitong Pharmaceutical Co. After the completion of the transaction, Jiyao Holdings will hold 10% of Haitong Pharmaceutical; on June 26, the general manager of Jiyao Holdings agreed to buy 70% of Merlot Pharmaceutical with cash of 28 million yuan; on July 26, the board of directors agreed that the listed company would buy 100% of Arida Capsules with 230 million yuan, and after the transaction was completed, the listed company would increase its capital by 300 yuan. 0 million yuan.
On August 29, Jinbao Pharmaceutical Co., a subsidiary, intends to purchase 67,000 shares of Puhua Pharmaceutical Co., Ltd. held by Zhang Youjun at the price of 11.60 yuan per share, and on August 31, Jiyao Holdings Co., Ltd. will purchase 100,000 shares of Puhua Pharmaceutical Co., Ltd. held by Mohongli, etc. The two share purchase amounted to 1 million 937 thousand and 200 yuan.
Kyrgyzstan holdings this year, more than 1 billion yuan of the big buy buy buy, behind the market reaction?
According to the announcement, the Shenzhen Stock Exchange has issued two restructuring inquiries. After answering the inquiries, Jiyao Holdings announced that its shares will reopen in the morning of October 29.
After suspension for more than 4 months, Kyrgyzstan holdings resumed its trading limit for two consecutive trading days. According to Wind data, in the first week of the resumption of licensing, Kyrgyzstan held a three rise in the share price. After closing on November 2, the companys market value dropped from 5.188 billion yuan before resumption to 4.163 billion yuan, evaporating more than 1 billion yuan in a week.
Regarding the sharp decline and fluctuation of stock prices, Jiyao Holdings told Xinjing News that the trend of stock prices in the secondary market is affected by multiple factors, we will try our best to do our job and strive to improve the companys performance.
As for the companys performance, the third quarter report of 2018 shows that the business income of Jiyao Holdings in the first nine months is about 602 million yuan, an increase of 14.36% over the same period of last year; the net profit of shareholders belonging to listed companies is about 102 million yuan, an increase of 1% over the same period of last year; the net profit of shareholders belonging to listed companies is deducted unless the recurring gains and losses are approximately equal. It was 0.54 billion yuan, a decrease of 19.59% over the same period last year, and the net cash flow generated by business activities was about 0.25 billion yuan, a decrease of 59.93% over the same period last year.
The Beijing News reporter noted that the government subsidy for Ji Medicine Holdings accounted for 56 million yuan in the first 9 months of 2018. According to this calculation, the government subsidies obtained by Jiyao Holdings account for 55.36% of the net profits attributable to the shareholders of listed companies.
The chairman encouraged employees to increase their holdings, which has lost 2 million yuan this year.
On October 26, Jiyao Holdings issued a proposal to increase the companys stock ownership issued by its chairman to its employees in the announcement.
Sun Jun, chairman and general manager of the company, advocated that all employees of the company and its wholly-owned subsidiaries and holding subsidiaries should actively buy the companys stock, and promised that the employees should confirm the quantity they intend to buy beforehand, and use their own funds to buy Jiyao Holdings through bidding in the secondary market from the opening date to 30 trading dates. Stocks are held for more than 12 consecutive months and the employees who are in service shall be compensated by themselves for the losses actually incurred by buying the companys stocks during the preceding period, and the profits shall be owned by the employees themselves; if the reduction occurs for 12 consecutive months, or if the employees are not in service from the time of purchase to the time when they are compensated by themselves, they shall not be allowed to do so. Compensation.
Regarding the chairmans suggestion that employees should increase their ownership of the companys stocks and promise to go to the bottom, Jiyao Holdings responded to the reporter of the Beijing News that Chairman Sun Juns proposal is based on his judgment of the companys investment value and confidence in the future development of the enterprise. This proposal is not linked to the companys performance. Employees are in the secondary market at the market price. The company buys shares of the company on its own.
On October 30th, in the supplementary announcement of the proposal for increasing share ownership, the reporter of the Beijing News noticed that as of the announcement date, 978 employees of the company, wholly-owned subsidiaries and holding subsidiaries were employed. The per capita remuneration of the companys employees is about 36953 yuan / year. According to this calculation, the average monthly salary of the employees is 3079.42 yuan. By the end of November 2nd, the price of Ji Medicine Holdings was 6.25 yuan per share.
The Beijing News reporter noted that since the listing of Ji medicine holding company, Sun Jun has increased holdings of listed companies several times. The last time was from February 2 to 5, 2018, Sun Jun increased his holding of 124.57 million shares in the secondary market through his account, which accounted for 0.187% of the companys total equity, and the total amount of the increase exceeded 10 million yuan.
After the increase, no record of Sun Juns reduction was found. According to the current stock price calculation, Sun Juns recent increase has lost about 2 million 217 thousand and 100 yuan.
Large shareholders holding a large proportion of pledge, or strong risk
Ji Pharmaceutical Holdings 2017 earnings report shows that the companys largest shareholder is Lu Zhongkui, the second largest shareholder is Sun Jun. Sun Jun was born in August 1965, graduated from the Party School of the Jilin provincial Party committee, a member of the CPC and a senior economist. Sun Jun was the deputy of Meihekou Peoples Congress, the Standing Committee of Meihekou Peoples Congress, the deputy of Tonghua Peoples Congress, the director of Tonghua Medical Association and the vice-president of Meihekou Industry and Commerce Association. From 1998 to 2013, Sun Jun was Chairman and General Manager of Jinbao Pharmaceutical Industry. From 2013 to now, Sun Jun was Chairman of Jinbao Pharmaceutical Industry, Legal Representative, Chairman and General Manager of Jibao Pharmaceutical Holdings.
According to the relevant announcement, the controlling shareholder of Ji Medicine Holdings is Lu Zhongkui. As of September 5, 2018, Luzhongkui owned 159 million shares of listed companies, accounting for 23.92% of the total equity of the company. Among them, 129 million shares were pledged, accounting for 80.85% of Luzhongkuis shares and 19.34% of the total equity of the company.
As of October 19, 2018, Sun Jun owned 940 million shares of listed companies, accounting for 14.11% of the companys total equity. Among them, the pledged shares were 072 million shares, accounting for 77.09% of its shares and 10.88% of the companys total equity.
In the announcement on October 30, Jiyao Holdings said that although Sun Jun and Lu Zhongkui had taken measures to deal with the risk of stock pledge, if the unreasonable arrangement of shareholdersfunds and poor turnover led to the impossibility of additional margin, supplementary pledge and early repurchase of shares, the Pledged Shares might be forced. Risks of closing positions.
This year, Kyrgyzstan controlled many acquisitions and investments.
On January 30, Jilin Pharmaceutical Holdings announced that it planned to invest 67.0625 million yuan to subscribe for the new registered capital of Haitong Pharmaceutical Co. After the completion of the transaction, Kyrgyzstan will hold 10% stake in Haitong pharmaceutical.
On April 19, Jiyao Holdings announced that it was planning to transfer 70% of Bozhou Pharmaceutical Holdings held by Minsheng Pharmaceutical Industry at a price of 0 yuan.
On April 19, Jiyao Holdings announced that it also intends to transfer 22%, 22% and 26% of Yuanda Kanghuas shares held by Zhao Ke, Liu Chengchao and Bai Guizhi at a price of 0 yuan.
On June 12, Jilin Pharmaceutical Holdings announced a major suspension announcement to purchase Puhua Pharmaceutical Equity, with the transaction value ranging from 750 million to 850 million yuan. In June 26th, the office of general manager of Jilin Pharmaceutical Holdings agreed to acquire 70% stake in Milo medicine in cash 28 million yuan. On July 26, the board of directors of the company agreed that the listed company would buy 100% of Arida Pills for 230 million yuan. After the transaction was completed, the listed company increased its capital by 30 million yuan. On August 29, Jinbao Pharmaceutical Company, a subsidiary, intends to acquire 67,000 shares of Puhua Pharmaceutical Company held by Zhang Youjun at the price of 11.60 yuan per share. In August 31st, Kyrgyzstan acquired 100 thousand shares of Pu Hua Pharmaceutical such as Mo Hongli. The two share purchase amounted to 1 million 937 thousand and 200 yuan. Source: Beijing News Editor: Zhao Yaping _NN9005
On June 12, Jilin Pharmaceutical Holdings announced a major suspension announcement to purchase Puhua Pharmaceutical Equity, with the transaction value ranging from 750 million to 850 million yuan.
In June 26th, the office of general manager of Jilin Pharmaceutical Holdings agreed to acquire 70% stake in Milo medicine in cash 28 million yuan.
On July 26, the board of directors of the company agreed that the listed company would buy 100% of Arida Pills for 230 million yuan. After the transaction was completed, the listed company increased its capital by 30 million yuan.
On August 29, Jinbao Pharmaceutical Company, a subsidiary, intends to acquire 67,000 shares of Puhua Pharmaceutical Company held by Zhang Youjun at the price of 11.60 yuan per share.
In August 31st, Kyrgyzstan acquired 100 thousand shares of Pu Hua Pharmaceutical such as Mo Hongli. The two share purchase amounted to 1 million 937 thousand and 200 yuan.